Tabelecleucel (Pierre Fabre Laboratories and Atara Biotherapeutics Inc.) is an investigational allogenic T cell immunotherapy proposed for treatment of relapsed or refractory Ebstein-Barr virus-positive posttransplant lymphoproliferative disease.
Tabelecleucel (Pierre Fabre Laboratories and Atara Biotherapeutics Inc.) is an investigational allogenic T cell immunotherapy proposed for treatment of relapsed or refractory Ebstein-Barr virus-positive posttransplant lymphoproliferative disease.